CSIMarket Company Name, Ticker, Customers, else..
 
Arca Biopharma Inc  (NASDAQ: ABIO)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 68
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -133
 Cash Flow (TTM) (Millions $) 60
 Capital Exp. (TTM) (Millions $) 0

Business Description


Arca Biopharma Inc is a biopharmaceutical company that focuses on the development and commercialization of treatments for cardiovascular diseases. The company primarily focuses on developing genetically-targeted therapies, using its proprietary technology to identify and select patients who are most likely to benefit from certain treatments. Arca Biopharma aims to improve the effectiveness and safety of current treatment options for cardiovascular diseases, such as heart failure and atrial fibrillation. They collaborate with leading academic institutions and research organizations to advance their drug development programs.


   Company Address: 10170 Church Ranch Way Westminster 80021 CO
   Company Phone Number: 940-2200   Stock Exchange / Ticker: NASDAQ ABIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
REGN        1.72% 
VRTX        1.93% 
AMGN        7.49% 
BCRX   -2.76%    
CLDX   -21.25%    
NVAX        6.1% 
• View Complete Report
   



Merger and Acquisition

The Combined Future: Arca Biopharma Inc Merges with Oruka Therapeutics, Inc and Takes the Nasdaq by Storm

Published Thu, Aug 29 2024 8:50 PM UTC

The Combined Future: Arca Biopharma Inc. Merges with Oruka Therapeutics, Inc. and Takes the Nasdaq by Storm
In a significant move poised to reshape the landscape of precision medicine for cardiovascular diseases, Arca Biopharma Inc. (NASDAQ: ABIO) has successfully completed its merger with Oruka Therapeutics, Inc. The newly formed entity will operate under the name Oruk...
Dividend

ARCA Biopharma Announces Attractive Special Dividend Amid Merger With Oruka Therapeutics: A Boost for Investors,

Published Mon, Aug 26 2024 11:30 PM UTC



ARCA Biopharma s Special Dividend Amid Merger Talks: What Investors Need to Know
On August 26, 2024, ARCA biopharma, Inc. (NASDAQ: ABIO) released a press statement announcing a special dividend of $1.613 per share of common stock, which is to be distributed on August 28, 2024. This dividend is a notable component of the company s forthcoming merger with Oruka ...
Merger and Acquisition

ARCA biopharma Reports Strong First Quarter 2024 Results and Unveils Promising Corporate Developments

Published Thu, Apr 25 2024 8:15 PM UTC


ARCA biopharma Inc, a leader in In Vitro & In Vivo Diagnostic Substances, recently announced their financial results for the first quarter of 2024. The company reported a market capitalization of $42 million, showcasing their strong position in the industry.
During the first quarter, ARCA biopharma saw significant growth in revenue and profits, demonstrating the eff...
Clinical Study

Advancing Treatment for Chronic Skin Diseases: The ARCA biopharma and Oruka Therapeutics Merger Agreement

Published Wed, Apr 3 2024 11:30 AM UTC

The recent merger agreement between ARCA biopharma and Oruka Therapeutics has paved the way for a new era in the treatment of chronic skin diseases. This anticipated merger aims to harness Oruka s innovative portfolio of novel biologics to redefine the standard of care for patients suffering from these debilitating conditions. This article delves into the facts surrounding t...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 87.05
Working Capital Ratio 87.48
Leverage Ratio (MRQ) 0.02
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.38 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,954,206
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.